Allinaire Therapeutics has been awarded a $1,670,000 Phase II SBIR grant from the National Heart, Lung, and Blood Institute (NHLBI) and a $213,000 Discovery Award from the department of Defence (DOD).
Allinaire Therapeutics aims to develop novel therapeutics for Chronic Obstructive Pulmonary Disease (COPD) and other pulmonary diseases. It is based on discoveries and intellectual property from the Indiana University School of Medicine, developed by scientific founders Irina Petrache, MD and Matthias Clauss, PhD.
